Skip Navigation

Key Eligibility Criteria for CAR T-Cell Therapy for Leukemia

  • Key eligibility criteria include:

    • Confirmed diagnosis of B-cell acute lymphoblastic leukemia (ALL) that has either not responded or has relapsed after at least two lines of prior treatment.
    • Adequate organ, cardiac, and pulmonary function (must meet established criteria/measures).
    • Age 25 years or younger.

    Patients may also be evaluated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center (Dana-Farber/Boston Children's).

  • Dana-Farber/ Brigham and Women's Cancer Center
  • Contact Information for CAR T-Cell Therapy

    For more information about CAR T-cell therapy, please call 877-801-CART (2278) or email cartinquiries@dfci.harvard.edu.

  • Pediatric CAR T-Cell Therapy

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).